The Centers for Disease Control and Prevention (CDC) recommends intramuscular penicillin G benzathine as the preferred medication for treating primary, secondary, latent, and non-neurologic forms of tertiary syphilis.7
BICILLIN® L-A is the only formulation of intramuscular penicillin G benzathine that is FDA-approved for the treatment of syphilis. 10,12
Indications for BICILLIN® L-A include: 2
- Syphilis
- Infections due to penicillin-G-susceptible microorganisms susceptible to the low and very prolonged serum levels common to this particular dosage form
- Mild-to-moderate infections of the upper respiratory tract due to susceptible streptococci, including streptococcal pharyngitis
- Prophylaxis to prevent recurrence of rheumatic fever and/or chorea
Indications for BICILLIN® C-R include:
- Moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form, including the following infections: 3
- Moderately severe to severe infections of the upper respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci
- Moderately severe pneumonia and otitis media due to susceptible pneumococci
BICILLIN® at a Glance
What makes BICILLIN® L-A and BICILLIN® C-R different? Knowing is essential for healthcare professionals.3 Understand BICILLIN® at a glance.
BICILLIN® L-A (penicillin G benzathine injectable suspension) is indicated in the treatment of infections due to penicillin G sensitive microorganisms that are susceptible to the low and very prolonged serum levels provided by this particular dosage form. These include mild-to-moderate upper respiratory tract infections due to susceptible streptococci (including streptococcal pharyngitis), syphilis, yaws, bejel, and pinta. It is also indicated as prophylactic treatment for rheumatic fever and glomerulonephritis.
BICILLIN® C-R (penicillin G benzathine and penicillin G procaine injectable suspension) is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. These include upper respiratory tract infections, scarlet fever, erysipelas, skin and soft-tissue infections due to susceptible streptococci, and pneumonia and otitis media due to susceptible pneumococci. NOTE: This formulation should not be used in the treatment of venereal disease, including syphilis.
Important Safety Information for BICILLIN® L-A and BICILLIN® C-R
Do not inject intravenously or admix with other intravenous solutions. There have been reports of inadvertent intravenous administration of penicillin G benzathine which has been associated with cardiorespiratory arrest and death.
Penicillin G is contraindicated in patients with a history of hypersensitivity reactions to any of the penicillins and BICILLIN® C-R in patients with a history of hypersensitivity reaction to procaine. Before use, identify previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. If allergic reaction occurs, discontinue use and initiate appropriate therapy.
Pseudomembranous colitis has been reported with nearly all antibacterial agents, including penicillin, and may range in severity from mild to life-threatening.
Give only by deep intramuscular injection. Do not inject into or near nerves or arteries; severe neurovascular or other damage may occur. Adverse reactions include but are not limited to: gastrointestinal, hypersensitivity, central nervous system, dermatologic, hematologic, and injection site reactions.
Please see accompanying full Prescribing Information for BICILLIN® L-A and BICILLIN® C-R.
The information on this site is intended for U.S. healthcare professionals only.
All Rights Reserved. Terms of Access | Privacy Policy